Clinical trial
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
NCT00080535 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00080535 |
|---|---|
| Title | Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas |
| Official title | A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, T-Cell, Cutaneous |
| Intervention type | Biological |
| Interventions | LMB-2 |
| Enrollment | 10 |
| Start date | Apr 30, 2004 |
| Primary completion | Dec 31, 2011 |
| Completion | Dec 31, 2011 |
| First posted | Apr 7, 2004 |
| Last update posted | Jan 29, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: